Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Ariel International Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Ariel International Fund employs a disciplined, non-consensus value approach to invest in misunderstood, undervalued global companies. Despite declining -5.11% in Q4 2024, the fund outperformed major international benchmarks."
Ariel International Fund operates on a non-consensus value philosophy, seeking to identify undervalued, out-of-favor global franchises that are fundamentally mispriced. During the quarter ended December 31, 2024, the fund declined -5.11%, outperforming its primary MSCI EAFE and secondary MSCI ACWI ex-US benchmarks, which dropped -8.11% and -7.60% respectively. Key performance contributors included Fresenius Medical Care, Banca Monte dei Paschi, and Emaar Properties, which gained on robust earnings and positive corporate milestones. Conversely, Michelin, Sanofi, and JD.com detracted due to temporary macro headwinds and political noise. Management capitalized on market volatility by initiating seven new positions, including Barclays and Orange SA, while exiting fully valued names like Munich Re and Safran. Looking ahead, the manager expects heightened market volatility from US policy uncertainty and rate cuts. However, they see this environment as highly conducive for active value managers, as international equities trade at attractive discounts to their US peers.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
Assigned 0.65. The fund holds a diversified list of positions with clear individual theses but also added a developed markets ETF as a cash alternative, signaling some near-term tactical flexibility.
Growth Outlook
The manager rates the market outlook at 0.65. While acknowledging significant headwinds in the US, Eurozone, and China, they remain highly constructive on the valuation and earnings resilience of international equities relative to their US peers.
Risk Appetite
Assigned 0.70 because the fund actively initiated seven new positions and added to others, showing a clear willingness to deploy capital despite predicting heightened market volatility.
Capital Deployment
Assigned 0.85 due to significant activity this quarter: initiating seven new positions (including Barclays, Beazley, and Orange) and exiting five names (such as Munich Re and Safran) on valuation.
Forward Guidance
Assigned 0.60 as the manager is focused on identifying mispriced opportunities and utilizing active management to navigate upcoming policy and interest rate shifts.
Language Signal
Assigned 0.75. The language used is predominantly constructive and opportunistic, highlighting 'undervalued, out-of-favor' franchises and 'attractive valuation levels,' despite discussing macro challenges.
Perceived Risk
Assigned 0.65. The manager highlights several specific macro risks, including sluggish growth in China, potential tariff implications, Eurozone interest rate uncertainty, and policy changes under the new US administration.
Opportunity Density
Assigned 0.80. The manager notes that they are finding 'many mispriced global and international stocks trading at a discount,' which is validated by their purchase of seven new holdings.
Time Horizon
Assigned 0.75, citing their core belief that 'stock prices trade on fundamentals' over the long run and their explicitly 'patient' investment philosophy.
